Carregando...
Sophoridine suppresses lenvatinib‐resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression
Hepatocellular carcinoma (HCC) is one of the most lethal cancer types with insufficient approved therapies, among which lenvatinib is a newly approved multi‐targeted tyrosine kinase inhibitor for frontline advanced HCC treatment. However, resistance to lenvatinib has been reported in HCC treatment r...
Na minha lista:
| Publicado no: | J Cell Mol Med |
|---|---|
| Principais autores: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7810959/ https://ncbi.nlm.nih.gov/pubmed/33210432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.16108 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|